Skip to main content

Table 2 Treatment-emergent adverse events with a ≥ 5% frequency of occurrence in either galcanezumab dose group

From: A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

Event

Galcanezumab 120 mg

N = 129

n (%)

Galcanezumab 240 mg

N = 141

n (%)

Patient with ≥1 TEAE

106 (82.2)

121 (85.8)

Injection site pain

22 (17.1)

28 (19.9)

Nasopharyngitis

23 (17.8)

18 (12.8)

Upper respiratory tract infection

9 (7.0)

21 (14.9)

Injection site reaction

15 (11.6)

13 (9.2)

Back pain

12 (9.3)

15 (10.6)

Sinusitis

14 (10.9)

13 (9.2)

Nausea

10 (7.8)

9 (6.4)

Injections site erythema

9 (7.0)

9 (6.4)

Arthralgia

8 (6.2)

8 (5.7)

Influenza

8 (6.2)

8 (5.7)

Dizziness

5 (3.9)

9 (6.4)

Injection site bruising

5 (3.9)

8 (5.7)

Myalgia

8 (6.2)

3 (2.1)

Weight increased

7 (5.4)

4 (2.8)

  1. TEAE treatment-emergent adverse events
  2. There were no statistically significant differences between dose groups in frequency of events